Boston Scientific (BSX) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.73
- Estimate
- $0.72
- Surprise
- +0.9%
- Score at report (before → after)
- 5.9 → 6.0/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Boston Scientific (BSX) beat the $0.72 estimate with adjusted EPS of $0.73 — a modest 0.9% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.9/10) to Hold at 6.0/10 after the report.
Coverage in the report window
- These Analysts Revise Their Forecasts On Boston Scientific After Q3 Results — benzinga, 2026-10-29
- Baird Maintains Outperform on Boston Scientific, Raises Price Target to $51 — benzinga, 2026-10-29
- Boston Scientific Overshadowed by Hackers, Headwinds, and Lower Guidance — benzinga, 2026-10-28
Where TrendMatrix's rating stands now
TrendMatrix currently rates BSX Hold at 6.0/10.
4 of the last 4 quarters beat the estimate; this quarter's +0.9% surprise compares with a +2.2% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Concentration risk — Supplier: single-source components
- Below 200-MA, MA slope -12.1%/30d (confirmed downtrend)
- Momentum score 4.4/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $42.43
- Price target
- $51.60
- Stop
- $39.46
- Upside to target
- +21.6%
- Reward-to-risk
- 3.0:1
The stock trades at 17.9× trailing but 12.8× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: trading volume is running 4.0× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
BSX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $61.49B
- P/E (fwd)
- 12.8
- P/E (ttm)
- 17.9
- 52-week range
- $39.57–$105.65
- Off 52-week high
- 59.8%
- RSI (14)
- 52
- Volume vs avg
- 3.96×
- Score today
- 6.0/10